DTB: Perampanel as add-on treatment for epilepsy

Source: DTB Area: Evidence > Drug Specific Reviews Perampanel (Fycompa) is a new antiepileptic drug marketed in the EU as adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged ?12 years. The Drug and Therapeutics Bulletin (DTB) discusses its place in therapy.   The following points are highlighted:   . In adults and children aged ?12 years with poorly controlled focal (partial-onset) epilepsy, perampanel modestly reduces the frequency of seizures when used as adjunctive therapy.   . The number needed to treat to achieve at least a 50% reduction in seizure frequency in patients treated with perampanel (with one to three concurrent antiepileptic drugs) was 5.   . The proportion of patients reporting complete freedom from seizures was 5% with the highest dose of perampanel.   . Unwanted effects are dose-related, with dizziness and somnolence the most likely.   . The cost ...
Source: NeLM - Drug Specific Reviews - Category: Drugs & Pharmacology Source Type: news